Tyrosine Kinase Inhibitors

A compound of the formula:

• wherein X is a bond, O, CR3′R4′, S or NR5;
• R1 is heteroaryl or aryl, wherein said heteroaryl and aryl groups are optionally substituted with one to three groups independently selected from the group consisting of halo, cyano, C1-6 alkyl, (C1-6 alkyl)R7, heterocyclyl, OR10 and (C═O)N(R5)(R6);
• R2 is heteroaryl or phenyl, wherein said heteroaryl group is optionally substituted with one to two groups independently selected from the group consisting of halo, cyano, N(R5)(R6), OR10, R9, heterocyclyl, (aryl)R9 and (heteroaryl)R9;
• and wherein said phenyl group is optionally substituted with one to two substituents independently selected from the group consisting of:
• (1) halo,
• (2) hydroxyl,
• (3) cyano,
• (4) heterocyclyl,
• (5) heteroaryl, which is optionally substituted with N(R5)(R6), OR10, R9, heterocyclyl, (aryl)R9 or (heteroaryl)R9,
• (6) NH(C═O)C1-5 alkyl, wherein said alkyl group is optionally substituted with one to three R8,
• (7) NH(C═O)OC1-5 alkyl, wherein said alkyl group is optionally substituted with one to three R8, and
• (8) NH(C═O)NHR11,
• R3 is hydrogen, C1-6 alkyl or halo,
• R4 is hydrogen, C1-6 alkyl or halo,
• R3′ is hydrogen, C1-6 alkyl or halo,
• R4′ is hydrogen, C1-6 alkyl or halo,
• wherein R3 and R3′ can be taken together with the carbon atoms to which they are attached to form a C3-6 cycloalkyl ring,
• R5 is hydrogen or C1-6 alkyl;
• R6 is hydrogen or C1-6 alkyl;
• R7 is hydrogen, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, heterocyclyl, OR10, (C═O)N(R5)(R6) or N(R5)(R6);
• R8 is hydrogen, halo, hydroxyl, C1-6 alkyl, OR10, C1-6 haloalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl(R5), N(R5)(R6), N(R5)-phenyl, (C═O)N(R5)(R6), phenyl, heteroaryl or heterocyclyl, wherein said heterocyclyl group is optionally substituted with one to three groups independently selected from the group consisting of halo, hydroxyl, C1-6 alkyl, (C1-6 alkyl)OR5, C1-6 haloalkyl, SO2 and (C═O)OH;
• R9 is hydrogen, heterocyclyl, (C═O)N(R5)(R6), N(R5)(R6), C3-8 cycloalkyl or C1-6 alkyl, wherein said alkyl is optionally substituted with one to four groups independently selected from the group consisting of halo, hydroxyl, O(C1-6 alkyl), heterocyclyl, aryl and heteroaryl;
• R10 is hydrogen, heterocyclyl, C3-8 cycloalkyl or C1-6 alkyl, wherein said alkyl is optionally substituted with one to four groups independently selected from the group consisting of halo, hydroxyl, O(C1-6 alkyl), heterocyclyl, aryl and heteroaryl;
• R11 is hydrogen, C1-6 alkyl or C3-8 cycloalkyl, wherein said alkyl is optionally substituted with one to three R8;
• or a pharmaceutically acceptable salt thereof.